{
    "Trade/Device Name(s)": [
        "Ceruloplasmin"
    ],
    "Submitter Information": "Beckman Coulter Ireland Inc.",
    "510(k) Number": "K161508",
    "Predicate Device Reference 510(k) Number(s)": [
        "K053074"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "DDB"
    ],
    "Summary Letter Date": "November 28, 2016",
    "Summary Letter Received Date": "December 8, 2016",
    "Submission Date": "May 26, 2016",
    "Regulation Number(s)": [
        "21 CFR 866.5210"
    ],
    "Regulation Name(s)": [
        "Ceruloplasmin Immunological Test System"
    ],
    "Analyte Class(es)": [
        "chemistry"
    ],
    "Analyte(s)": [
        "Ceruloplasmin"
    ],
    "Specimen Type(s)": [
        "Serum",
        "Plasma (Sodium Heparin and Lithium Heparin)"
    ],
    "Specimen Container(s)": [],
    "Instrument(s)/Platform(s)": [
        "Beckman Coulter AU Clinical Chemistry analyzers"
    ],
    "Method(s)/Technology(ies)": [
        "Immunoturbidimetric"
    ],
    "Methodologies": [],
    "Submission Type(s)": [
        "Reagent",
        "Calibrator"
    ],
    "Document Summary": "FDA 510(k) summary for Beckman Coulter Ceruloplasmin reagent for quantitative measurement in serum and plasma using immunoturbidimetric method on AU analyzers",
    "Indications for Use Summary": "System reagent for the quantitative determination of Ceruloplasmin in human serum and plasma on Beckman Coulter AU analyzers as an aid in the diagnosis of copper metabolism disorders",
    "fda_folder": "Immunology"
}